Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, Morningstar.com reports. The firm had revenue of $0.23 million for the quarter.
Shares of NAVB stock traded down $0.04 during trading hours on Thursday, hitting $0.21. 22,715 shares of the company’s stock traded hands, compared to its average volume of 369,270. Navidea Biopharmaceuticals has a 12-month low of $0.13 and a 12-month high of $0.47.
ILLEGAL ACTIVITY NOTICE: “Navidea Biopharmaceuticals (NAVB) Posts Quarterly Earnings Results” was originally reported by WKRB News and is the property of of WKRB News. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.wkrb13.com/2018/11/08/navidea-biopharmaceuticals-navb-posts-quarterly-earnings-results.html.
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.
Further Reading: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.